Vivos (RDGL) Other financing activities (2011 - 2025)

Vivos (RDGL) reported Other financing activities of $1500.0 for Q1 2025, down 85.0% sequentially from $10000.0 in Q2 2018.

Vivos (RDGL) Other financing activities (2011 - 2025) Analysis & Trends

Vivos (RDGL) has 7 years of Other financing activities data on file, last reported at $1500.0 in Q1 2025.

For the quarter ending Q1 2025, Other financing activities changed N/A year-over-year to $1500.0; the trailing twelve-month figure through Dec 2025 stood at $1500.0 (changed N/A YoY), and the FY2025 full-year result was $1500.0, down 92.25% from the prior year.
Other financing activities declined to $1500.0 in Q1 2025, from $10000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $1500.0 in Q1 2025 to a low of $1500.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	183.90 Bn	176.61 Bn	6.27 Bn
2	Stryker	128.85 Bn	125.97 Bn	3.81 Bn
3	Medtronic	108.77 Bn	99.55 Bn	6.41 Bn
4	Boston Scientific	68.39 Bn	66.93 Bn	3.61 Bn
5	Edwards Lifesciences	48.50 Bn	44.83 Bn	1.29 Bn
6	GE HealthCare Technologies	28.36 Bn	26.08 Bn	1.98 Bn
7	Dexcom	28.36 Bn	27.24 Bn	750.30 Mn
8	Smith & Nephew	26.92 Bn	26.35 Bn	-
9	Koninklijke Philips	25.48 Bn	22.35 Bn	2.07 Bn
10	Vivos	26.71 Mn	25.15 Mn	-3,105.00

Download Data